Assess whether RWE can replace or only supplement an RCT (b29ba1)

Situation

RWE can replace or sits with pharmacovigilance medical reviewer because a boxed-warning proposal from the review division hit a mid-size sponsor after a complete response letter. Evidence is disproportionate reporting signal workbook; write the Pharma & Life Sciences CMC and Development Pathways option that extract can carry.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose RWE can replace / Only supplement an RCT using disproportionate reporting signal workbook after a boxed-warning proposal from the review division.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend RWE can replace from disproportionate reporting signal workbook after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend RWE can replace from disproportionate reporting signal workbook; Only supplement an RCT is what the extract actually supports after a boxed-warning proposal from the review division.
• A boxed-warning proposal from the review division never reached the population in disproportionate reporting signal workbook — reopen intake, do not close RWE can replace or.
• Two facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division conflict for pharmacovigilance medical reviewer; hold this CMC and Development Pathways file.

Analysis required

• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read disproportionate reporting signal workbook against a boxed-warning proposal from the review division and write the one fact that would move RWE can replace or for pharmacovigilance medical reviewer.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / CMC and Development Pathways packet (disproportionate reporting signal workbook after a boxed-warning proposal from the review division). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.